© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
April 15th 2021, 1:00pm
Antibiotics, corticosteroids and proton pump inhibitors could cause negative impacts on survival in patients with non-small cell lung cancer who are receiving treatment with Keytruda.
March 26th 2021, 1:00pm
Rozlytrek continues to demonstrate clinical benefit for patients with ROS1 fusion-positive non-small cell lung cancer, which includes patients with central nervous system metastases.
December 3rd 2020, 10:00pm
Chimeric antigen receptor (CAR)-T cell therapy is becoming more widely available, with two drugs approved to treat specific blood cancers and more being investigated in clinical trials across cancer types. Here’s what patients need to know if they’re considering treatment with one of these novel immunotherapies.
October 14th 2020, 1:00pm
In an interview with CURE®, Dr. Trisha Wise-Draper discusses new findings that show an increased mortality risk for patients with cancer receiving systemic treatments who subsequently contracted COVID-19.
July 28th 2020, 10:06pm
The microorganisms inside a patient's gastrointestinal tract may have a role to play in how immunotherapy can treat certain types of cancer.
July 22nd 2020, 7:52pm
More than half of the patients (61%) admitted to either the hospital or ICU were discharged and 12% remained in the hospital. Nine patients had died by the time data collection was cut off for this study.
July 6th 2020, 10:54pm
Immunotherapy is a wonderful testament to the benefits that arise from our growing understanding of the incredibly intricate human immune system.
July 6th 2020, 5:00pm
In the 2020 special issue of CURE on Immunotherapy, we take a look at how the field of immunotherapy continues to grow despite challenges from the COVID-19 pandemic.
July 5th 2020, 6:00pm
Cutting-edge medical information and first-person accounts empower patients to evaluate immunotherapy as a treatment option, one organization attests.
June 30th 2020, 7:00pm
Across cancer types, a unique immune-stimulating treatment called tumor-infiltrating lymphocyte therapy produces durable remissions that could last for decades.
Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation
FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer
Learning to be a Kinder Person After Cancer